© 1996 American Heart Association, Inc.
Articles |
Lipoprotein(a) in Stored Plasma Samples and the Ravages of Time
Why Epidemiological Studies Might Fail
the Institute of Medical Biology and Human Genetics, University of Innsbruck (Austria).
Correspondence to Dr Florian Kronenberg, Institute of Medical Biology and Human Genetics, University of Innsbruck, Schopfstr 41, A-6020 Innsbruck, Austria. E-mail Florian.Kronenberg@uibk.ac.at.
Prospective case-control studies investigating lipoprotein(a) [Lp(a)] as a risk factor for atherosclerosis have measured Lp(a) in samples stored frozen up to nearly 20 years. We therefore prospectively examined the influence of long-term plasma sample storage on measured values, depending on the molecular weight of apolipoprotein(a) [apo(a)] isoforms. Apo(a) phenotyping was performed in 310 plasma samples, and Lp(a) was measured after 3 and 28 months of storage at -80°C. The values of both measurements correlated significantly for both low- and high-molecular-weight apo(a) phenotypes (r=.97 and r=.98, respectively, P<.001). Nevertheless, we detected on average a small decrease of 4.83% from mean±SD (median) 21.24±23.54 (11.10) mg/dL to 20.02±21.72 (10.55) mg/dL, which was statistically significant (P<.001). The absolute and relative Lp(a) decrease over time became larger with a decreasing number of kringle IV repeats of apo(a) (P<.05), and Lp(a) decreased markedly more in subjects with low-molecular-weight compared with those with high-molecular-weight apo(a) isoforms (-3.26 versus -0.46 mg/dL, P<.05). More than 70% of the absolute Lp(a) decrease in the total sample was caused by samples with low-molecular-weight apo(a) isoforms, which represented only 27% of the sample. Low-molecular-weight apo(a) isoforms are reportedly more frequent in patients with atherothrombotic disease compared with control subjects. Measurement of Lp(a) in several-year-old frozen samples is therefore likely to result in a preferential decrease and false lower Lp(a) concentrations in patient groups compared with control groups. The negative results of some prospective studies with retrospective measurement of Lp(a) may be caused by such an artifact.
Key Words: lipoproteins • apolipoproteins • sample storage • epidemiological studies • glycoproteins
This article has been cited by other articles:
 |
|
 |
|
  M. Mackness and E. Hughes Variability in the measurement of lipoprotein(a) in the British Isles Ann Clin Biochem, July 1, 2009; 46(4): 311 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Kamstrup, M. Benn, A. Tybjaerg-Hansen, and B. G. Nordestgaard Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study Circulation, January 15, 2008; 117(2): 176 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Suk Danik, N. Rifai, J. E. Buring, and P. M Ridker Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA, September 20, 2006; 296(11): 1363 - 1370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ohira, P. J. Schreiner, J. D. Morrisett, L. E. Chambless, W. D. Rosamond, and A. R. Folsom Lipoprotein(a) and Incident Ischemic Stroke: The Atherosclerosis Risk in Communities (ARIC) Study Stroke, June 1, 2006; 37(6): 1407 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Shai, E. B. Rimm, S. E. Hankinson, C. Cannuscio, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? Eur. Heart J., August 2, 2005; 26(16): 1633 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Solfrizzi, F Panza, A D'Introno, A M Colacicco, C Capurso, A M Basile, and A Capurso Lipoprotein(a), apolipoprotein E genotype, and risk of Alzheimer's disease J. Neurol. Neurosurg. Psychiatry, June 1, 2002; 72(6): 732 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Simo, J. Camps, E. Vilella, F. Gomez, A. Paul, and J. Joven Instability of Lipoprotein(a) in Plasma Stored at -70 {degrees}C : Effects of Concentration, Apolipoprotein(a) Genotype, and Donor Cardiovascular Disease Clin. Chem., September 1, 2001; 47(9): 1673 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. WAHN, V. DANIEL, F. KRONENBERG, G. OPELZ, D. V. MICHALK, and U. QUERFELD Impact of Apolipoprotein(a) Phenotypes on Long-Term Renal Transplant Survival J. Am. Soc. Nephrol., May 1, 2001; 12(5): 1052 - 1058. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. von Eckardstein, H. Schulte, P. Cullen, and G. Assmann Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk J. Am. Coll. Cardiol., February 1, 2001; 37(2): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Danesh, R. Collins, and R. Peto Lipoprotein(a) and Coronary Heart Disease : Meta-Analysis of Prospective Studies Circulation, September 5, 2000; 102(10): 1082 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lippi and G. Guidi Lipoprotein(a): from ancestral benefit to modern pathogen? QJM, February 1, 2000; 93(2): 75 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Harjai Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen Ann Intern Med, September 7, 1999; 131(5): 376 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Notsu, T. Nabika, H.-Y. Park, J. Masuda, and S. Kobayashi Evaluation of Genetic Risk Factors for Silent Brain Infarction Stroke, September 1, 1999; 30(9): 1881 - 1886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Periard, A. Telenti, P. Sudre, J.-J. Cheseaux, P. Halfon, M. J. Reymond, S. M. Marcovina, M. P. Glauser, P. Nicod, R. Darioli, et al. Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors Circulation, August 17, 1999; 100(7): 700 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Querfeld, S. Döpper, A. Gradehand, P. Kiencke, F. Wahn, and H.-J. Zeisel Long-Term Treatment with Growth Hormone Has No Persisting Effect on Lipoprotein(a) in Patients with Turner's Syndrome J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 967 - 970. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. L. Rainwater, C. A. McMahan, G. T. Malcom, W. D. Scheer, P. S. Roheim, H. C. McGill Jr, and J. P. Strong Lipid and Apolipoprotein Predictors of Atherosclerosis in Youth : Apolipoprotein Concentrations Do Not Materially Improve Prediction of Arterial Lesions in PDAY Subjects Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 753 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Craig, L. M. Neveux, G. E. Palomaki, M. M. Cleveland, and J. E. Haddow Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies Clin. Chem., November 1, 1998; 44(11): 2301 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. F. Wilson and W. B. Kannel Should We Measure Lipoprotein Lp(a)? Arch Intern Med, June 9, 1997; 157(11): 1161 - 1162. [Abstract] [PDF]
|
|